Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Ticker SymbolGCTK
Company nameGlucoTrack Inc
IPO dateApr 09, 2013
CEOMr. Paul V. Goode, Ph.D.
Number of employees11
Security typeOrdinary Share
Fiscal year-endApr 09
Address301 Rt 17 North
CityRUTHERFORD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07070
Phone197286757878
Website
Ticker SymbolGCTK
IPO dateApr 09, 2013
CEOMr. Paul V. Goode, Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data